Alembic Pharma amongst top 12 stocks to keep a eye on by ede
Alembic Pharmaceuticals Alembic Pharma, is a leader in several sub-segments of the Anti-Infective Therapeutic segment. Over the last two to three years, it has invested heavily in increasing its revenue contribution from chronic therapies & regulated markets, which are high margins businesses The company has increased its revenues from the chronic segment from 45 percent to over 50 percent currently over the last year growing at over 20 percent in the chronic segment, and intends to increase its share further. As a result, we expect the company’s domestic formulation business to grow at 12 percent CAGR over FY13-15E The company continues to improve its margins year-on-year, the company has ended FY13 at 16 percent EBITDA margins, and plans to improve it further by 100-125 bps every year, and expects margins to stabilize at 20 percent over the next 2-3 years Facility expansion for US, would start contributing from Q2FY14, which would help the company grow its US business at 25-30 percent CAGR from USD 20-30 mn currently to over USD 80-100 mn. The company has strong enough pipeline of filings in the US to support the growth. We expect the company’s international generic sales to grow at a CAGR of 28 percent over FY13-15E Negligible debt on books, company plans to become ZERO debt by FY15E
Read more at: http://www.moneycontrol.com/news/news/12-stocks-you-should-keepeye-on-edelweiss_987593.html?utm_source=ref_article
Alembic Pharmaceuticals Alembic Pharma, is a leader in several sub-segments of the Anti-Infective Therapeutic segment. Over the last two to three years, it has invested heavily in increasing its revenue contribution from chronic therapies & regulated markets, which are high margins businesses The company has increased its revenues from the chronic segment from 45 percent to over 50 percent currently over the last year growing at over 20 percent in the chronic segment, and intends to increase its share further. As a result, we expect the company’s domestic formulation business to grow at 12 percent CAGR over FY13-15E The company continues to improve its margins year-on-year, the company has ended FY13 at 16 percent EBITDA margins, and plans to improve it further by 100-125 bps every year, and expects margins to stabilize at 20 percent over the next 2-3 years Facility expansion for US, would start contributing from Q2FY14, which would help the company grow its US business at 25-30 percent CAGR from USD 20-30 mn currently to over USD 80-100 mn. The company has strong enough pipeline of filings in the US to support the growth. We expect the company’s international generic sales to grow at a CAGR of 28 percent over FY13-15E Negligible debt on books, company plans to become ZERO debt by FY15E
Read more at: http://www.moneycontrol.com/news/news/12-stocks-you-should-keepeye-on-edelweiss_987593.html?utm_source=ref_article
Alembic Pharmaceuticals Alembic Pharma, is a leader in several sub-segments of the Anti-Infective Therapeutic segment. Over the last two to three years, it has invested heavily in increasing its revenue contribution from chronic therapies & regulated markets, which are high margins businesses The company has increased its revenues from the chronic segment from 45 percent to over 50 percent currently over the last year growing at over 20 percent in the chronic segment, and intends to increase its share further. As a result, we expect the company’s domestic formulation business to grow at 12 percent CAGR over FY13-15E The company continues to improve its margins year-on-year, the company has ended FY13 at 16 percent EBITDA margins, and plans to improve it further by 100-125 bps every year, and expects margins to stabilize at 20 percent over the next 2-3 years Facility expansion for US, would start contributing from Q2FY14, which would help the company grow its US business at 25-30 percent CAGR from USD 20-30 mn currently to over USD 80-100 mn. The company has strong enough pipeline of filings in the US to support the growth. We expect the company’s international generic sales to grow at a CAGR of 28 percent over FY13-15E Negligible debt on books, company plans to become ZERO debt by FY15E
Read more at: http://www.moneycontrol.com/news/news/12-stocks-you-should-keepeye-on-edelweiss_987593.html?utm_source=ref_article
Alembic Pharmaceuticals Alembic Pharma, is a leader in several sub-segments of the Anti-Infective Therapeutic segment. Over the last two to three years, it has invested heavily in increasing its revenue contribution from chronic therapies & regulated markets, which are high margins businesses The company has increased its revenues from the chronic segment from 45 percent to over 50 percent currently over the last year growing at over 20 percent in the chronic segment, and intends to increase its share further. As a result, we expect the company’s domestic formulation business to grow at 12 percent CAGR over FY13-15E The company continues to improve its margins year-on-year, the company has ended FY13 at 16 percent EBITDA margins, and plans to improve it further by 100-125 bps every year, and expects margins to stabilize at 20 percent over the next 2-3 years Facility expansion for US, would start contributing from Q2FY14, which would help the company grow its US business at 25-30 percent CAGR from USD 20-30 mn currently to over USD 80-100 mn. The company has strong enough pipeline of filings in the US to support the growth. We expect the company’s international generic sales to grow at a CAGR of 28 percent over FY13-15E Negligible debt on books, company plans to become ZERO debt by FY15E
Read more at: http://www.moneycontrol.com/news/news/12-stocks-you-should-keepeye-on-edelweiss_987593.html?utm_source=ref_article